Intuitive Surgical Stock Is On Sale, But Is The Growth Story Changing?
The robotic surgery leader’s shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.
At Intuitive Surgical (ISRG), it’s a tale of two very different stories right now. On one hand, hospitals are eagerly buying the company’s new da Vinci 5 systems, with placements jumping 18% in the second quarter. On the other, growth in the critical U.S. market for the robotic procedures themselves has slowed. Management noted on its latest call that “Growth in the US moderated from recent trends,” pointing to potential insurance-related delays for some patients. The market has noticed the disconnect, and the stock has fallen about 23% from its recent high.
For an investor, this is the classic fork in the road. Is this a temporary blip for a dominant company, creating a rare discount? Or is it the first sign of a maturing market that no longer justifies a premium price? Let’s look at the evidence.
What Happened After Past Intuitive Surgical Selloffs
A sharp pullback in a stock like Intuitive Surgical is not unprecedented. Since 2010, the stock has suffered a drop of 20% or more within a single month on 10 separate occasions. History offers a moderately encouraging, though not perfect, script for what happened next. Of those 10 dips, exactly 5 were followed by a positive return over the next year. The median return twelve months later was 29%. Buying the dip wasn’t a pain-free experience, but it was manageable; investors who bought in typically saw the stock fall another 8% before it found a bottom.
ISRG had 10 events since 1/1/2010 where the dip threshold of -20% within 30 days was triggered
- 38% median peak return within 1 year of dip event
- 286 days is the median time to peak return after a dip event
- -8.3% median max drawdown within 1 year of dip event
| Period | Past Median Return |
|---|---|
| 1M | 7.5% |
| 3M | 7.4% |
| 6M | 8.0% |
| 12M | 29% |
| 30 Day Dip | ISRG Subsequent Performance | |||||||
|---|---|---|---|---|---|---|---|---|
| Date | ISRG | SPY | 1Y | Peak Return |
Max Drop |
# Days to Peak |
||
| Median | 29% | 38% | -8% | 286 | ||||
| 7232026 | -22% | 0% | 0% | 0 | ||||
| 4042025 | -24% | -16% | -0% | 31% | -5% | 277 | ||
| 9262022 | -21% | -14% | 55% | 89% | -3% | 295 | ||
| 5062022 | -20% | -9% | 34% | 36% | -19% | 362 | ||
| 1212022 | -21% | -6% | -4% | 13% | -32% | 70 | ||
| 3162020 | -28% | -25% | 80% | 103% | -9% | 298 | ||
| 5142014 | -25% | 0% | 35% | 49% | -2% | 341 | ||
| 7192013 | -23% | 5% | -1% | 38% | -10% | 258 | ||
| 3152013 | -20% | 5% | -7% | 12% | -23% | 84 | ||
| 8262010 | -20% | -4% | 29% | 54% | -8% | 329 | ||
[2] Analysis for period from 1/1/2010 to 7/23/2026
First, Is Intuitive Surgical Still A Quality Business?
Of course, buying a dip only makes sense if the business itself is still in excellent health. A falling stock price doesn’t always mean a broken company. On that front, Intuitive Surgical scores well. The business clears every basic quality check on a simple scorecard of growth, cash generation, and balance-sheet strength. Trailing twelve-month revenue grew a healthy 21%, and its operating cash flow margin stands at a strong 34%, signaling a business that turns sales into cash with impressive efficiency.
| Quality Metrics | Value | Quality Check |
|---|---|---|
| Revenue Growth (LTM) | 21% | Pass |
| Revenue Growth (3-Yr Avg) | 18.4% | Pass |
| Operating Cash Flow Margin (LTM) | 34% | Pass |
Is The Dip Buy Going To Work This Time?
So, is this dip an opportunity? The case for it rests on the company’s quality and its history. You have a market leader with a solid track record of bouncing back from pullbacks. The strong demand for its latest da Vinci 5 platform shows that hospitals remain committed to its technology for the long haul, and international procedure growth remains strong, running at 20% outside the U.S. We have looked at the key questions for the stock before, and this resilience is a core part of the bull case.
The hesitation comes from two places: the price and the pace. Even after its decline, ISRG stock trades at a price-to-earnings ratio of about 37, a significant premium to the 24 multiple of its peer group. You are not getting an absolute bargain. More importantly, that premium is being tested by the slowdown in U.S. procedure growth to 12%. While management believes this is temporary, some analysts are asking if it could be something more permanent, like market maturation. As one analyst on the call put it, “Other med tech companies are not calling it out or seeing it.”
Ultimately, the decision rests on whether you believe the U.S. slowdown is a fleeting issue or the start of a new, slower chapter. The historical odds have been decent for dip-buyers here, but they weren’t a sure thing. The one thing to watch is that U.S. procedure volume. If it reaccelerates in the coming quarters, today’s price may look like a gift. If it stays sluggish, that premium valuation will be much harder to defend.
Which Other Quality Names Just Went On Sale?
The same two questions you just asked about Intuitive Surgical apply to every pullback: has the stock fallen far enough to matter, and does its kind of dip tend to recover. Plenty of other quality names sell off in any given week, and most never make the headlines. Our Buy The Dip rankings screen the market’s recent declines and how past dips of that size have played out, so you can see which discounts have history on their side before you act. And if you would rather own the whole group than bet on one name’s rebound, a healthcare ETF like XLV holds the entire basket.
What Makes A Dip Worth Buying Again And Again?
The reason dip-buying works over time is not luck, it is quality: strong businesses fall with the market and then climb back, while weak ones fall and stay down. The hard part is doing it consistently, across enough names that one stubborn laggard does not undo a year of good calls. A single dip is a coin you have to flip perfectly; a basket of quality dips is a process.
The Trefis High Quality (HQ) Portfolio turns that process into a system, holding the 30 strongest names, sized and rebalanced with rules so you are always buying quality and never resting the year on one rebound. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. It is how you keep the upside of buying the dip without the white-knuckle risk of doing it one stock at a time.